UNION therapeutics presents new data on orismilast at the 31st EADV Congress supporting orismilast’s potential as a first-in-class or best-in-class treatment for certain immunological diseases
Preclinical data presented in the oral presentation demonstrate that orismilast is a potent inhibitor of phosphodiesterase type-4 (PDE4), and that orismilast more selectively inhibit PDE4B and PDE4D subtypes which are […]
UNION therapeutics announces regulatory approval of Treatment Extension for the ongoing OSIRIS Phase 2a open label study with orismilast MR tablet for patients with Hidradenitis Suppurativa (HS)
OSIRIS is an investigator-initiated Phase 2a open label study, studying orismilast modified release (MR) tablet as a potential treatment for HS Treatment Extension gives the possibility to allow patients to […]
UNION therapeutics announces presentation of new data on orismilast at the 31st EADV Congress
Oral presentation of new preclinical data on pharmacological properties of orismilast at the EADV Congress Additional e-poster details the safety and efficacy of orismilast IR (immediate release) tablets in adults […]
UNION therapeutics completes patient enrollment in the IASOS Phase 2b study of orismilast MR tablet in patients with psoriasis
Topline results expected in first half of 2023 Orismilast is a potent next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) […]
UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis
ADESOS is a Phase 2b dose-finding study of orismilast modified release (MR) tablet in moderate to severe atopic dermatitis (AD) with the purpose of identifying the appropriate dose-regimen for Phase […]
UNION therapeutics announces expansion to India of the PROTECT-V Phase 2/3 study of niclosamide nasal spray as COVID-19 prophylaxis
The PROTECT-V Phase 2/3 platform study investigating niclosamide nasal spray as prophylactic treatment for COVID-19 in kidney patients will now be conducted in both the UK and India UK investigators […]
UNION therapeutics announces full year results for 2021 with significant advancement of the clinical pipeline, expansion of international collaborations and strengthening of the organization
Hellerup, Denmark, 17 March 2022 – UNION therapeutics A/S (“UNION”), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, announces the full year results […]
UNION therapeutics announces enrollment of first patient in the IASOS Phase 2b study of oral orismilast in psoriasis patients
IASOS is a Phase 2b dose-ranging study of oral orismilast in psoriasis patients with the purpose of identifying the appropriate dose-regimen for Phase 3 studies Orismilast is a next generation […]
UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis
FDA’s Fast Track designation for oral orismilast underscores the urgent need for new treatment option with potential to fulfil the unmet medical needs for people affected by atopic dermatitis (AD) […]
UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa
OSIRIS is an investigator-led, proof-of-concept Phase 2 study of orismilast for the treatment of mild to severe hidradenitis suppurativa (HS) HS is a scarring inflammatory skin disease with significant unmet […]
